Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
| Autor: | Carol S. Connor, Shane R. Stecklein, Catherine J. Knight, Claire Ward, Marilee McGinness, Andrew K. Godwin, Carol J. Fabian, Roy A. Jensen, Joshua Mv Mammen, Qamar J. Khan, Jonathan D. Mahnken, Lori Ranallo, Jennifer R. Klemp, Manana Elia, Priyanka Sharma, Jamie L. Wagner, Larry J. Geier, Bruce F. Kimler |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Population Prevalence Breast Neoplasms Triple Negative Breast Neoplasms Article Breast cancer Internal medicine medicine Humans Genetic Predisposition to Disease Genetic Testing Prospective Studies Registries Family history education Prospective cohort study Triple-negative breast cancer Aged Genetic testing Aged 80 and over BRCA2 Protein Ovarian Neoplasms Gynecology education.field_of_study medicine.diagnostic_test BRCA1 Protein business.industry BRCA mutation Middle Aged medicine.disease Mutation Hereditary Breast and Ovarian Cancer Syndrome Female business |
| Zdroj: | Breast Cancer Research and Treatment. 145:707-714 |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-014-2980-0 |
| Popis: | NCCN guidelines recommend genetic testing for all triple-negative breast cancer (TNBC) patients aged ≤60 years. However, due to the lack of prospective information in unselected patients, these guidelines are not uniformly adopted by clinicians and insurance carriers. The aim of this study was to determine the prevalence of BRCA mutations and evaluate the utility of NCCN guidelines in unselected TNBC population. Stage I–IV TNBC patients were enrolled on a prospective registry at academic and community practices. All patients underwent BRCA1/2 testing. Significant family history (SFH) was defined >1 relative with breast cancer at age ≤50 or ≥1 relative with ovarian cancer. Mutation prevalence in the entire cohort and subgroups was calculated. 207 TNBC patients were enrolled between 2011 and 2013. Racial/ethnic distribution: Caucasian (80 %), African–American (14 %), Ashkenazi (1 %). Deleterious BRCA1/2 mutations were identified in 15.4 % (32/207) of patients (BRCA1:11.1 %, BRCA2:4.3 %). SFH reported by 36 % of patients. Mutation prevalence in patients with and without SFH was 31.6 and 6.1 %, respectively. When assessed by age at TNBC diagnosis, the mutation prevalences were 27.6 % (≤50 years), 11.4 % (51–60 years), and 4.9 % (≥61 years). Using SFH or age ≤50 as criteria, 25 and 34 % of mutations, respectively, were missed. Mutation prevalence in patients meeting NCCN guidelines was 18.3 % (32/175) and 0 % (0/32) in patients who did not meet guidelines (p = .0059). In this unselected academic and community population with negligible Ashkenazi representation, we observed an overall BRCA mutation prevalence rate of 15.4 %. BRCA testing based on NCCN guidelines identified all carriers supporting its routine application in clinical practice for TNBC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink